Just caught wind of something interesting in the biotech space that's worth discussing. Intellia Therapeutics has been on quite a run this year—up 47%—and there's actually a solid story behind the move.

For those not familiar, this is one of Cathie Wood's picks through Ark Invest. Cathie Wood has made a name for herself backing companies with real innovative potential, and Intellia definitely fits that mold. It's a mid-cap biotech focused on gene editing, which is honestly one of the more fascinating frontiers in medicine right now.

So what's driving the recent momentum? The company was dealing with a pretty serious regulatory headwind. The FDA had put clinical holds on two phase 3 studies for one of their lead candidates, nex-z, after a patient death linked to liver failure. That obviously tanked the stock at the time. But here's the thing—the FDA just lifted those clinical holds, which means Intellia can move forward with their studies. That's a huge relief for investors who believed in the thesis, and it explains why we're seeing this bounce back.

Their pipeline includes lonvo-z for hereditary angioedema and nex-z for transthyretin amyloidosis. The amyloidosis opportunity is particularly interesting because there are hundreds of thousands of patients globally, and nex-z would be a one-time treatment if it works. They've also got Regeneron as a partner, which adds credibility.

But here's where I think you need to pump the brakes a bit. The real concern nobody's fully answered yet: did nex-z actually cause that liver failure, or was it coincidental? The company won't say definitively, and neither will regulators. They're taking more precautions now—excluding certain patients, monitoring liver inflammation more carefully—but that underlying question mark is still there. For a gene editing therapy, which already faces adoption challenges because of cost and complexity, a lingering safety question is the last thing you need.

Gene editing medicines are tough sells to insurance companies and healthcare systems to begin with. Add potential safety concerns on top of that, and you've got real headwinds. There's also the standard clinical and regulatory risks that could derail things.

So is it too late to buy after a 47% run? Honestly, depends on your risk tolerance. The upside could be significant if nex-z proves safe and effective. But the downside risks are real too. This isn't a stock for conservative investors. If you're comfortable with volatility and believe in the Cathie Wood thesis on gene editing, it might be worth a small position. Otherwise, probably worth watching from the sidelines for now.